Soluble fms-like tyrosine kinase-1 (sFLT-1) predicts post-percutaneous coronary intervention (PCI) myocardial infarction (MI type 4a)

Biomarkers

Volumn 17, Issue 8, 2012, Pages 730-737

  Searle, Julia ^a   Slagman, Anna ^a   Gwosc, Stefanie ^a   Vollert, Jörn Ole ^a   Holert, Fabian ^a   Müller, Christian ^a   Muller, Reinhold ^b   Möckel, Martin ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b JAMES COOK UNIVERSITY   (Australia)

Author keywords

Cardiovascular disease; Growth factors cytokines inflammatory mediators

Indexed keywords

TROPONIN; VASCULOTROPIN RECEPTOR 1;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; ENDOTHELIAL DYSFUNCTION; FEMALE; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT IDENTIFICATION; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE; PROGNOSIS; PROTEIN BLOOD LEVEL; REFERENCE VALUE; RISK ASSESSMENT;

AGED; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT (HEALTH CARE); PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REGRESSION ANALYSIS; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84870512460     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2012.725428     Document Type: Article

References (32)

1. Bonzel T, Erbel R, Hamm CW, Levenson B, Neumann FJ, Rupprecht HJ, Zahn R. (2008). [Percutaneous coronary interventions (PCI)]. Clin Res Cardiol 97:513-547.
2. Chung NA, Lydakis C, Belgore F, Li-Saw-Hee FL, Blann AD, Lip GY. (2003). Angiogenesis, thrombogenesis, endothelial dysfunction and angiographic severity of coronary artery disease. Heart 89:1411-1415.
3. Cuisset T, Hamilos M, Melikian N, Wyffels E, Sarma J, Sarno G, Barbato E, Bartunek J, Wijns W, De Bruyne B. (2008). Direct stenting for stable angina pectoris is associated with reduced periprocedural microcirculatory injury compared with stenting after pre-dilation. J Am Coll Cardiol 51:1060-1065.
4. Dasgupta A, Mukherjee D. (2009). Use of clopidogrel in the reduction of myocardial damage during percutaneous coronary intervention. Vasc Health Risk Manag 5:275-286.
5. Fujii K, Kawasaki D, Oka K, Akahori H, Iwasaku T, Fukunaga M, Eguchi A, Sawada H, Masutani M, Lee-Kawabata M, Tsujino T, Ohyanagi M, Masuyama T. (2011). The impact of pravastatin pretreatment on periprocedural microcirculatory damage in patients undergoing percutaneous coronary intervention. JACC Cardiovasc Interv 4:513-520.
6. Herrmann J. (2005). Peri-procedural myocardial injury: 2005 update. Eur Heart J 26:2493-2519.
7. Hochholzer W, Reichlin T, Stelzig C, Hochholzer K, Meissner J, Breidthardt T, Reiter M, Duehsler B, Freidank H, Winkler K, Twerenbold R, Mueller C. (2011). Impact of soluble fms-like tyrosine kinase-1 and placental growth factor serum levels for risk stratification and early diagnosis in patients with suspected acute myocardial infarction. Eur Heart J 32:326-335.
8. Hong YJ, Mintz GS, Kim SW, Lee SY, Okabe T, Pichard AD, Satler LF, Waksman R, Kent KM, Suddath WO, Weissman NJ. (2009). Impact of plaque composition on cardiac troponin elevation after percutaneous coronary intervention: an ultrasound analysis. JACC Cardiovasc Imaging 2:458-468.
9. Hoole SP, Heck PM, Sharples L, Dutka DP, West NE. (2010). Coronary stent length predicts PCI-induced cardiac myonecrosis. Coron Artery Dis 21:312-317.
10. Kapur NK, Heffernan KS, Yunis AA, Nguyen TA, Aronovitz MJ, Parpos P, Wilson S, Baker CK, Esposito ML, Shah A, Kimmelstiel CD, Weintraub A, Karas RH, Mendelsohn ME. (2011). Elevated soluble fms-like tyrosine kinase-1 levels in acute coronary occlusion. Arterioscler Thromb Vasc Biol 31:443-450.
11. Lee CH, Low A, Tai BC, Co M, Chan MY, Lim J, Lim YT, Tan HC. (2007). Pretreatment with intracoronary adenosine reduces the incidence of myonecrosis after non-urgent percutaneous coronary intervention: a prospective randomized study. Eur Heart J 28:19-25.
12. Mandadi VR, DeVoe MC, Ambrose JA, Prakash AM, Varshneya N, Gould RB, Nguyen TH, Geagea JP, Radojevic JA, Sehhat K, Barua RS. (2004). Predictors of troponin elevation after percutaneous coronary intervention. Am J Cardiol 93:747-750.
13. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA. (2003). Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111:649-658.
14. Milani RV, Fitzgerald R, Milani JN, Lavie CJ. (2009). The impact of micro troponin leak on long-term outcomes following elective percutaneous coronary intervention. Catheter Cardiovasc Interv 74:819-822.
15. Moulton KS. (2001). Plaque angiogenesis and atherosclerosis. Curr Atheroscler Rep 3:225-233.
16. Moulton KS, Vakili K, Zurakowski D, Soliman M, Butterfield C, Sylvin E, Lo KM, Gillies S, Javaherian K, Folkman J. (2003). Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci USA 100:4736-4741.
17. Muller R, Möckel M. (2008). Logistic regression and CART in the analysis of multimarker studies. Clin Chim Acta 394:1-6.
18. Natarajan MK, Kreatsoulas C, Velianou JL, Mehta SR, Pericak D, Goodhart DM. (2004). Incidence, predictors, and clinical significance of troponin-I elevation without creatine kinase elevation following percutaneous coronary interventions. Am J Cardiol 93:750-753.
19. Onoue K, Uemura S, Takeda Y, Somekawa S, Iwama H, Nishida T, Morikawa Y, Nakagawa H, Tsutsumi T, Sung JH, Takemoto Y, Soeda T, Okayama S, Ishigami K, Kawata H, Horii M, Nakajima T, Saito Y. (2009). Usefulness of soluble Fms-like tyrosine kinase-1 as a biomarker of acute severe heart failure in patients with acute myocardial infarction. Am J Cardiol 104:1478-1483.
20. Orecchia A, Lacal PM, Schietroma C, Morea V, Zambruno G, Failla CM. (2003). Vascular endothelial growth factor receptor-1 is deposited in the extracellular matrix by endothelial cells and is a ligand for the alpha 5 beta 1 integrin. J Cell Sci 116:3479-3489.
21. Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G. (2005). Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 111:2099-2106.
22. Porto I, Selvanayagam JB, Van Gaal WJ, Prati F, Cheng A, Channon K, Neubauer S, Banning AP. (2006). Plaque volume and occurrence and location of periprocedural myocardial necrosis after percutaneous coronary intervention: insights from delayedenhancement magnetic resonance imaging, thrombolysis in myocardial infarction myocardial perfusion grade analysis, and intravascular ultrasound. Circulation 114:662-669.
23. Prasad A, Herrmann J. (2011). Myocardial infarction due to percutaneous coronary intervention. N Engl J Med 364:453-464.
24. Prasad A, Singh M, Lerman A, Lennon RJ, Holmes DR Jr, Rihal CS. (2006). Isolated elevation in troponin T after percutaneous coronary intervention is associated with higher long-term mortality. J Am Coll Cardiol 48:1765-1770.
25. Searle J, Danne O, Müller C, Mockel M. (2011a). Biomarkers in acute coronary syndrome and percutaneous coronary intervention. Minerva Cardioangiol 59:203-223.
26. Searle J, Mockel M, Gwosc S, Datwyler SA, Qadri F, Albert GI, Holert F, Isbruch A, Klug L, Muller DN, Dechend R, Muller R, Vollert JO, Slagman A, Mueller C, Herse F. (2011b). Heparin strongly induces soluble fms-like tyrosine kinase 1 release in vivo and in vitro-brief report. Arterioscler Thromb Vasc Biol 31:2972-2974.
27. Selvanayagam JB, Porto I, Channon K, Petersen SE, Francis JM, Neubauer S, Banning AP. (2005). Troponin elevation after percutaneous coronary intervention directly represents the extent of irreversible myocardial injury: insights from cardiovascular magnetic resonance imaging. Circulation 111:1027-1032.
28. Shibuya M. (2006). Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis. Angiogenesis 9:225-30; discussion 231.
29. Silber S, Albertsson P, Avilés FF, Camici PG, Colombo A, Hamm C, Jørgensen E, Marco J, Nordrehaug JE, Ruzyllo W, Urban P, Stone GW, Wijns W; Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. (2005). Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 26:804-847.
30. Steppich BA, Kaufmann J, Sepp D, Kunert K, Rutz T, Stratz C, Ott I. (2009). Increased circulating placental growth factor during percutaneous coronary intervention is associated with applied radiocontrast agent. Coron Artery Dis 20:130-137.
31. Testa L, Van Gaal WJ, Biondi Zoccai GG, Agostoni P, Latini RA, Bedogni F, Porto I, Banning AP. (2009). Myocardial infarction after percutaneous coronary intervention: a meta-analysis of troponin elevation applying the new universal definition. QJM 102:369-378.
32. Thygesen K, Alpert JS, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. (2007). Universal definition of myocardial infarction. Eur Heart J 28:2525-2538.